MX9405380A - Benzotiofenos y benzofuranos como agentes de uso terapeutico en eltratamiento de enfermedades inflamatorias del intestino y metodos contrala inflamacion. - Google Patents

Benzotiofenos y benzofuranos como agentes de uso terapeutico en eltratamiento de enfermedades inflamatorias del intestino y metodos contrala inflamacion.

Info

Publication number
MX9405380A
MX9405380A MX9405380A MX9405380A MX9405380A MX 9405380 A MX9405380 A MX 9405380A MX 9405380 A MX9405380 A MX 9405380A MX 9405380 A MX9405380 A MX 9405380A MX 9405380 A MX9405380 A MX 9405380A
Authority
MX
Mexico
Prior art keywords
benzotiofenos
benzofuranos
intestine
agents
treatment
Prior art date
Application number
MX9405380A
Other languages
English (en)
Inventor
James Alan Dykens
Joseph Edward Low
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9405380A publication Critical patent/MX9405380A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención hace un uso novedoso de los conocidos benzotiofenoso benzofuranos y sales farmacéuticamente aceptables de ellos. Talescomponentes como el 5-metoxi-3-(1-metiletoxi)-N-1H-tetrazol-5-ilbenzo[b]tiofeno-2-carboxamida se usa para tratar enfermedades inflamatorias delintestino como la enfermedad de Crohn y la colitis ulcerativa. La presenteinvención también es un ensayo para monitorear no invasivamente lainflamación.
MX9405380A 1993-07-15 1994-07-14 Benzotiofenos y benzofuranos como agentes de uso terapeutico en eltratamiento de enfermedades inflamatorias del intestino y metodos contrala inflamacion. MX9405380A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9204593A 1993-07-15 1993-07-15

Publications (1)

Publication Number Publication Date
MX9405380A true MX9405380A (es) 1995-01-31

Family

ID=22231123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9405380A MX9405380A (es) 1993-07-15 1994-07-14 Benzotiofenos y benzofuranos como agentes de uso terapeutico en eltratamiento de enfermedades inflamatorias del intestino y metodos contrala inflamacion.

Country Status (6)

Country Link
EP (1) EP0789569A2 (es)
JP (1) JPH09500130A (es)
AU (1) AU7396194A (es)
CA (1) CA2163542A1 (es)
MX (1) MX9405380A (es)
WO (1) WO1995002406A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60105195T2 (de) 2000-12-05 2005-09-08 F. Hoffmann-La Roche Ag Benzofuran- und benzothiophen-derivative als selektive cox-2 inhibitoren
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
MXPA05013210A (es) * 2003-06-05 2006-03-09 Warner Lambert Co Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release

Also Published As

Publication number Publication date
EP0789569A2 (en) 1997-08-20
WO1995002406A2 (en) 1995-01-26
CA2163542A1 (en) 1995-01-26
AU7396194A (en) 1995-02-13
WO1995002406A3 (en) 1995-04-27
JPH09500130A (ja) 1997-01-07

Similar Documents

Publication Publication Date Title
Henderson et al. Phantom limbs
Fisher Pure sensory stroke involving face, arm, and leg
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
Silversides The neurological sequelae of electrical injury
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
Tolosa et al. Meige's disease: A clinical form of facial convulsion, bilateral and medial
AR058359A1 (es) Combinaciones
PT933995E (pt) Metodo para tratamento de lesao endotelial
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
Sefiddashti et al. The effects of cryotherapy versus cryostretching on clinical and functional outcomes in athletes with acute hamstring strain
AR047005A1 (es) Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico
AU2014210332B2 (en) Method of treating fibrosis in skeletal muscle tissue
Sandyk et al. Further observations on the unique efficacy of picoTesla range magnetic fields in Parkinson's Disease
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
MX9405380A (es) Benzotiofenos y benzofuranos como agentes de uso terapeutico en eltratamiento de enfermedades inflamatorias del intestino y metodos contrala inflamacion.
ES2635421T3 (es) Composiciones farmacéuticas que comprenden (S)-(+)-7-(1H-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para tratar enfermedades y trastornos cutáneos
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
Rudy Imiquimod (Aldara): modifying the immune response
BRPI0409387A (pt) método para o tratamento de doença de tecido mole em um indivìduo mamìfero, composição farmacêutica, complexo de alvejamento de tecido mole, método para a formação de um complexo, e, kit para uso em um método
Sankhala et al. Spoke-wheel injuries
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
ATE245448T1 (de) Zellwachstumshemmende zusammensetzungen die kalzium-zufluss-blocker enthalten